Spots Global Cancer Trial Database for dabrafenib mesylate

Every month we try and update this database with for dabrafenib mesylate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer	NCT01902173	Hematopoietic a... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Mela... Stage IIIC Cuta... Stage IV Cutane... Unresectable Ma... Unresectable Me...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Magnetic Resona... Trametinib Dime... Uprosertib	18 Years -	National Cancer Institute (NCI)
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	NCT04557956	Clinical Stage ... Metastatic Mela...	Biopsy Computed Tomogr... Dabrafenib Mesy... Echocardiogram ... Magnetic Resona... Multigated Acqu... Tazemetostat Hy... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	NCT04527549	Clinical Stage ... Locally Advance... Pathologic Stag... Pathologic Stag... Unresectable Me...	Dabrafenib Mesy... Hydroxychloroqu... Placebo Adminis... Trametinib Dime...	18 Years -	Eastern Cooperative Oncology Group
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery	NCT01947023	Metastatic Thyr... Unresectable Th...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	NCT02224781	Clinical Stage ... Clinical Stage ... Metastatic Mela... Recurrent Melan... Unresectable Me...	Biospecimen Col... Computed Tomogr... Dabrafenib Mesy... Echocardiograph... Ipilimumab Multigated Acqu... Nivolumab Quality-of-Life... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	NCT04439292	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Dabrafenib Mesy... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery	NCT01947023	Metastatic Thyr... Unresectable Th...	Biopsy Biospecimen Col... Computed Tomogr... Dabrafenib Dabrafenib Mesy... Echocardiograph... Lapatinib Lapatinib Ditos... Magnetic Resona... Multigated Acqu... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma	NCT04527549	Clinical Stage ... Locally Advance... Pathologic Stag... Pathologic Stag... Unresectable Me...	Dabrafenib Mesy... Hydroxychloroqu... Placebo Adminis... Trametinib Dime...	18 Years -	Eastern Cooperative Oncology Group
Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)	NCT04439292	Advanced Lympho... Advanced Malign... Hematopoietic a... Refractory Lymp... Refractory Mali... Refractory Mult...	Dabrafenib Mesy... Trametinib Dime...	18 Years -	National Cancer Institute (NCI)
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma	NCT03919071	Anaplastic Astr... Anaplastic Astr... Anaplastic Gang... Anaplastic Pleo... Glioblastoma Malignant Gliom... WHO Grade 3 Gli...	Biospecimen Col... Dabrafenib Mesy... Lumbar Puncture Magnetic Resona... Radiation Thera... Trametinib Dime...	12 Months - 21 Years	National Cancer Institute (NCI)

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: